Animal models of portal hypertension

Biochim Biophys Acta Mol Basis Dis. 2019 May 1;1865(5):1019-1030. doi: 10.1016/j.bbadis.2018.07.018. Epub 2018 Jul 25.

Abstract

Chronic liver diseases ultimately lead to cirrhosis and portal hypertension (PHT). Indeed, PHT is a major cause of severe complications, while medical treatment is limited to non-selective beta blockers. Sophisticated animal models are needed to investigate novel treatment options for different etiologies of liver disease, effective anti-fibrotic agents as well as vasoactive drugs against PHT. In this review, we present some of the most common animal models of liver disease and PHT - including pre-hepatic, intra-hepatic and post-hepatic PHT in rodents. Methodology for induction, considerations for disease etiology, advantages and limitations and practical issues of these animal models are discussed. The appropriate and sensible use of animal models in preclinical research supporting the 3R concept of replacement, reduction and refinement is highlighted.

Keywords: Animal model; BDL; CCl(4); Cirrhosis; HFD; Liver disease; MCD; NASH; NCPH; PPVL; Portal hypertension; TAA.

Publication types

  • Review

MeSH terms

  • Animals
  • Disease Models, Animal*
  • Humans
  • Hypertension, Portal / chemically induced
  • Hypertension, Portal / drug therapy
  • Hypertension, Portal / genetics
  • Hypertension, Portal / pathology*
  • Mice
  • Research Design / standards